TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07803588: A Study to Test the AdaptDx Pro Agreement in Rod Intercept Time With the AdaptDx in Healthy Subjects With Normal Vision (FlashBack)

Sponsor: AdaptDx, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$6,407,600

Rescue Site Savings

+$4,216,400

Unlock Full NCT07803588 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07803588 Rescue Dossier →